Table 2.
List of cell lines used in this study.
| Cell line | Origin | CD112 (fold MFI*) | CD155 (fold MFI*) | WT NK-92 (%CD56+CD107a+) | DNAM-1+NK-92 (%CD56+CD107a+) |
|---|---|---|---|---|---|
| K562 (ATCC® CCL-243™) | Chronic myelogenous leukemia | 99.05 | 1.36 | 71.7 (±5.9) | 81.3 (±6.5) |
| THP-1 (ATCC® TIB-202™) | Acute monocytic leukemia | 64.83 | 0.94 | 23.4 (±6.7) | 60.7 (±11.7) |
| U266 (ATCC® TIB-196™) | Myeloma; plasmacytoma | 10.82 | 2.14 | 38.65 (±5) | 69.8 (±9.3) |
| RPMI8226 (ATCC® CCL-155™) | Myeloma; plasmacytoma | 1.16 | 1.24 | 10.5 (±2.9) | 18.5 (±3.6) |
| ARH-77 (ATCC® CRL-1621™) | Plasma cell leukemia | 3.22 | 0.59 | 11.7 (±0.4) | 39.1 (±9.4) |
| Caco-2 (ATCC® HTB-37™) | Primary colorectal adenocarcinoma | 59.73 | 4.06 | 4.7 (±1.1) | 46 (±10.3) |
| Capan-2 (ATCC® HTB-80™) | Primary pancreatic ductal adenocarcinoma | 50.92 | 4.73 | 5.3 (±1.9) | 45.4 (±9.4) |
| PC-3 (ATCC® CRL-1435™) | Metastatic prostate adenocarcinoma | 60.7 | 1.44 | 6.8 (±2.8) | 52.9 (±0.7) |
| LNCaP (ATCC® CRL-1740™) | Metastatic prostate carcinoma | 18.60 | 2.25 | 4.6 (±1.2) | 47.5 (±7.3) |
| A549 (ATCC® CCL-185™) | Primary lung alveolar basal cell epithelial adenocarcinoma | 85.31 | 6.69 | 7.7 (±3.6) | 41.5 (±7.9) |
| A375 (ATCC® CRL-1619™) | Malignant melanoma | 18.28 | 2.71 | 17.6 (±5.8) | 59.9 (±4) |
| DM6 (34) | Malignant melanoma | 51.67 | 2.76 | 23.3 (±7.5) | 53.5 (±7) |
| SK-MEL-28 (ATCC® HTB-72™) | Malignant melanoma | 60.45 | 4.75 | 7.9 (±2.1) | 36.8 (±8.3) |
| MeWo (ATCC® HTB-65™) | Malignant melanoma | 120.91 | 5.58 | 11.4 (±5.8) | 47.4 (±16.9) |
| SH-SY5Y (ATCC® CRL-2266™) | Metastatic neuroblastoma | 7.89 | 3.64 | 3.2 (±0.7) | 21.7 (±3.1) |
| sNF02.2 (ATCC® CRL-2885™) | Metastatic malignant peripheral nerve sheath tumor (MPNST) | 106.87 | 4.40 | 11 (±4) | 115 (±7.7) |
| Saos-2 (ATCC® HTB-85™) | Osteosarcoma | 59.46 | 5.28 | 9.4 (±4.9) | 43.8 (±16.4) |
| U-2 OS (ATCC® HTB-96™) | Osteosarcoma | 425.32 | 15.59 | 11.8 (±6.1) | 39.9 (±12.2) |
*
Calculated as (MFIstained – MFIunstained)/MFIunstained.